{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:07:04Z","timestamp":1773083224469,"version":"3.50.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2008,9,1]]},"DOI":"10.2174\/187153008785700118","type":"journal-article","created":{"date-parts":[[2008,9,2]],"date-time":"2008-09-02T22:01:51Z","timestamp":1220392911000},"page":"159-172","source":"Crossref","is-referenced-by-count":50,"title":["Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease"],"prefix":"10.2174","volume":"8","author":[{"given":"G.","family":"Cabral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Griffin-Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Endocrine\u201a Metabolic & Immune Disorders-Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/83116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T09:55:53Z","timestamp":1448272553000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1871-5303&volume=8&issue=3&spage=159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,1]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/187153008785700118","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9,1]]}}}